Skip to content
HCC Buddy home

HCC Buddy Code Book

Skip to code book content
HCC Buddy
HCC Buddy
Alphabetic Index and Tabular path
HCC Buddy public API, FY2026 Apr updateSource load source requiredSource year 2026Updated 2026-04-01

Index trail

Agranulocytosis secondary to cancer chemotherapy

See Tabular List: D70.1

D70, Neutropenia

D70.1, Agranulocytosis secondary to cancer chemotherapy

Selected code, source checked for the selected effective period

Commonly confused codes

official source

Not listed for this effective period.

Code details and official notes

D70.1

Agranulocytosis secondary to cancer chemotherapy

Open the shareable code page for D70.1→
billable

Includes

official source
  • agranulocytosis
  • decreased absolute neurophile count (ANC)

Excludes 1

official source
  • neutropenic splenomegaly (D73.81)
  • transient neonatal neutropenia (P61.5)

Excludes 2

official source

No Excludes 2 note is listed in this source payload.

Code First

official source

Not listed for this effective period.

Use Additional

official source
  • code for adverse effect, if applicable, to identify drug (T45.1X5)
  • code for any associated:
  • fever (R50.81)

Code Also

official source
  • underlying neoplasm
  • , if applicable, mucositis (J34.81, K12.3-, K92.81, N76.81)

7th character

official source

Not listed for this code in the selected Tabular payload.

Placeholder X

official source

Not listed for this code in the selected Tabular payload.

Laterality

official source

No laterality instruction is listed for this code in the selected Tabular payload.

Effective period

source required
  • FY2026 Apr update
  • Source year 2026
  • Updated 2026-04-01
  • HCC Buddy public API
HCC Buddy
HCC Buddy
Alphabetic Index and Tabular path
HCC Buddy public API, FY2026 Apr updateSource load source requiredSource year 2026Updated 2026-04-01

Index trail

Agranulocytosis secondary to cancer chemotherapy

See Tabular List: D70.1

D70, Neutropenia

D70.1, Agranulocytosis secondary to cancer chemotherapy

Selected code, source checked for the selected effective period

Commonly confused codes

official source

Not listed for this effective period.

Code details and official notes

D70.1

Agranulocytosis secondary to cancer chemotherapy

Open the shareable code page for D70.1→
billable

Includes

official source
  • agranulocytosis
  • decreased absolute neurophile count (ANC)

Excludes 1

official source
  • neutropenic splenomegaly (D73.81)
  • transient neonatal neutropenia (P61.5)

Excludes 2

official source

No Excludes 2 note is listed in this source payload.

Code First

official source

Not listed for this effective period.

Use Additional

official source
  • code for adverse effect, if applicable, to identify drug (T45.1X5)
  • code for any associated:
  • fever (R50.81)

Code Also

official source
  • underlying neoplasm
  • , if applicable, mucositis (J34.81, K12.3-, K92.81, N76.81)

7th character

official source

Not listed for this code in the selected Tabular payload.

Placeholder X

official source

Not listed for this code in the selected Tabular payload.

Laterality

official source

No laterality instruction is listed for this code in the selected Tabular payload.

Effective period

source required
  • FY2026 Apr update
  • Source year 2026
  • Updated 2026-04-01
  • HCC Buddy public API
HCC Buddy Insights

HCC Mapping

V28 source requiredHCC 47 Disorders of Immunity (V24)RxHCC source requiredHCC 47 Disorders of Immunity (ESRD/PACE)HHS-HCC source required or member context needed for selected effective period (HHS-HCC)

RAF Value

V28 RAF source requiredV24: RAF: 0.665RxHCC RAF source requiredESRD/PACE: RAF: 0.078HHS-HCC RAF source required

Model Period

FY2026 Apr update

Source

source required

Audit Caution

Close codes need documentation support before selection. Do not assume relationships.
Reviewed by Jess P., CPC

HCC Buddy workflow band

HCC mapping, RAF, MEAT, source trail, and audit caution stay in view.

MEAT supportaudit cautionsource required

V24

HCC 47

Disorders of Immunity

RAF: 0.665

ESRD/PACE

HCC 47

Disorders of Immunity

RAF: 0.078

HHS-HCC

source required

HHS-HCC source required or member context needed for selected effective period

RAF: source required

MEAT checklist

Reviewed by Jess P., CPC

Monitor, Evaluate, Assess, or Treat must be supported in the provider note.

HCC Buddy guidance, not official ICD-10-CM text.

Audit caution

Reviewed by Jess P., CPC

Close codes need documentation support before selection. Do not assume relationships.

HCC Buddy guidance, not official ICD-10-CM text.

Reviewer sign-off

Reviewed by Jess P., CPC

MEAT, documentation support, audit cautions, and close-code guidance are reviewed and approved for this effective period.

HCC Buddy enrichment is separate from official source text.

Last updated: April 1, 2026 · Not a substitute for official coding guidelines. No PHI or patient data.
HCC Buddy Code Card
FY 2026 Apr update
D70.1Billable

Agranulocytosis secondary to cancer chemotherapy

CMS-HCC V24

HCC 47

RAF 0.665

ESRD/PACE

HCC 47

RAF 0.078

ACA/HHS

Source required

RAF source required

Reviewed by Jess P., CPCFY2026 Apr update

Code

D70.1

V28 HCC

Not mapped

RAF

source required

Compare tray

Add close codes to compare documentation differences.